Navigation Links
Enbrel Will Remain Decision Resources' Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
Date:1/12/2010

y route and the potential for harmful side-effects are all drawbacks to current biologic agents used to treat TNF-alpha inhibitor-refractory patients. However, given a drug with incremental safety, delivery and even cost advantages, physicians are still unwilling to compromise on efficacy," stated Decision Resources Analyst Kyle Crowell.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Can Your Drug Gain An Edge in the TNF-Alpha Refractory Patient Segment of the Rheumatoid Arthritis Market? Exploring Drug Attributes Needed to Maximize Patient Share. This webinar will be held on Wednesday, January 27, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at gmorales@dresources.com.

About the Report

Rheumatoid Arthritis: Opportunity Awaits Therapies that Meet Physicians' Efficacy Expectations in TNF-α Inhibitor-Refractory Patients is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in mark
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
2. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
3. Senate Rejects Bulk Imports of Medicine from Canada, but Personal Importation Remains a Popular Option for U.S. Citizens
4. Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018
5. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
6. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
7. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
8. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
9. Cardiac Disease in Women Remains Untreated for Decades
10. Quality Colonoscopy Exam Remains Best Strategy for Detection of Polyps and Cancers According to Experts From the American College of Gastroenterology
11. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... sodium injection) were also ... within 90 days-, BRIDGEWATER, N.J., Dec 10 ... total hospital,direct medical costs associated with VTE treatment are ... the use of low-molecular weight heparin,(LMWH) vs. unfractionated heparin ...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today reported ... The company recorded a net loss of approximately ... for the fiscal quarter ended Oct. 31,compared to a ... and diluted,common share, for the first quarter of fiscal ...
Cached Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:1/22/2015)... 22, 2015 The Incredible Bulk is a ... to increase lean muscle by up to 30lbs in less ... attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , ... a step-by-step, scientific diet formula that allows the body to ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... , THURSDAY, April 21 (HealthDay News) -- Long-term ... condition known as eczema doesn,t cause any major negative side ... concerned about the use of corticosteroid creams or lotions applied ... eczema in children, the researchers explained. The most common fear ...
... Data and Safety Monitoring Committee (DSMC) has determined that ... in addition to a standard chemotherapy regimen for advanced ... progression-free survival than patients on the same chemotherapy regimen ... 1,000 patients who had advanced, hormone-refractory prostate cancer were ...
... happiest countries and happiest U.S. states tend to have the ... of Warwick, Hamilton College in New York and the Federal ... titled Dark Contrasts: The Paradox of High Rates of Suicide ... Journal of Economic Behavior & Organization . It uses ...
... Health at the Mailman School of Public Health report evidence ... and deficits in IQ and working memory at age seven. ... of prenatal chlorpyrifos exposure on cognitive development at the time ... Health Perspectives . Until banned for indoor residential ...
... among different breast cancer treatment options make smarter choices when ... than all at once, as is customary, a University of ... who aren,t good with numbers have a harder time understanding ... says Brian Zikmund-Fisher, assistant professor at the U-M School of ...
... ,Press registration is now open for Transcatheter Valve ... at http://www.tvtconference.com/conference/press-registration.html . TVT is a unique ... diagnostic and therapeutic options for the treatment of ... Late Breaking Clinical Data, Emerging Technologies: ...
Cached Medicine News:Health News:Corticosteroid Creams Safe for Kids With Eczema: Study 2Health News:Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer 2Health News:Happiest places have highest suicide rates says new research 2Health News:Happiest places have highest suicide rates says new research 3Health News:Prenatal exposure to common insecticide linked to decreases in cognitive functioning at age 7 2Health News:Presenting cancer treatment options in small doses yields smarter choices 2
... the iQ®200 Automated Urine Microscopy Analyzer ... Automated Urine Chemistry Analyzer (AX-4280) to ... microscopic analysis. The iQ200 uses Auto-Particle ... network, to classify and quantitate twelve ...
... The Sysmex UF-100 is designed to ... microscopic analysis. It combines the superior ... automated urine sample analysis. Continuous sampling ... the rack-based autosamplers, streamlining sample processing in ...
... easy to use Ambulatory Urodynamic recorder which ... practising urologists as an invaluable aid in ... The system offers the possibility to measure ... natural bladder filling, extented over a longer ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
Medicine Products: